Routine clinical evaluation of cerebrovascular reserve capacity using carbogen in patients with intracranial stenosis
Manus J Donahue1, Lindsey M Dethrage2, Carlos C Faraco2
1From the Departments of Radiology (M.J.D., L.M.D., C.C.F., A.D., J.C., M.K.S.), Neurology (M.J.D., L.C.J., P.C., A.O., D.R., L.H., H.K.), Psychiatry (M.J.D.), Physics (M.J.D.), and Neurosurgery (J.M., J.C., M.K.S.) and Center for Quantitative Sciences (Y.S.), Vanderbilt University, Nashville, TN; and Department of Neurosurgery, Geisel School of Medicine, Dartmouth College, Lebanon, NH (R.S.); mj.donahue@vanderbilt.edu.
Background And Purpose:
A promising method for identifying hemodynamic impairment that may serve as a biomarker for stroke risk in patients with intracranial stenosis is cerebrovascular reactivity (CVR) mapping using noninvasive MRI. Here, abilities to measure CVR safely in the clinic using hypercarbic hyperoxic (carbogen) gas challenges, which increase oxygen delivery to tissue, are investigated.
Methods:
In sequence with structural and angiographic imaging, blood oxygenation level-dependent carbogen-induced CVR scans were performed in patients with symptomatic intracranial stenosis (n=92) and control (n=10) volunteers, with a subgroup of patients (n=57) undergoing cerebral blood flow-weighted pseudocontinuous arterial spin labeling CVR. Subjects were stratified for 4 substudies to evaluate relationships between (1) carbogen and hypercarbic normoxic CVR in healthy tissue (n=10), (2) carbogen cerebral blood flow CVR and blood oxygenation level-dependent CVR in intracranial stenosis patients (n=57), (3) carbogen CVR and clinical measures of disease in patients with asymmetrical intracranial atherosclerotic (n=31) and moyamoya (n=29) disease, and (4) the CVR scan and immediate and longer-term complications (n=92).
Results:
Noninvasive blood oxygenation level-dependent carbogen-induced CVR values correlate with (1) lobar hypercarbic normoxic gas stimuli in healthy tissue (R=0.92; P<0.001), (2) carbogen-induced cerebral blood flow CVR in patients with intracranial stenosis (R=0.30-0.33; P<0.012), and (3) angiographic measures of disease severity both in atherosclerotic and moyamoya patients after appropriate processing. No immediate stroke-related complications were reported in response to carbogen administration; longer-term neurological events fell within the range for expected events in this patient population.
Conclusions:
Carbogen-induced CVR elicited no added adverse events and provided a surrogate marker of cerebrovascular reserve consistent with intracranial vasculopathy.
